A compound represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt thereof: in Chemical Formula 1, n is 1 or 2, L is -CH 2 CH 2 -, -CH=C(R')-, or -C≡C-, wherein R' is hydrogen, C 1-4 alkyl, or halogen, X 1 is CR 1 R 2 , NR 1 , or -CO-, X 2 is CR 3 R 4 , or NR 3 , wherein R 1 to R 4 are each independently hydrogen, C 1-4 alkyl, C 1-4 hydroxyalkyl, hydroxy, amino, carboxy, -COO(C 1-4 alkyl), -CONH 2 , -CONH(C 1-4 alkyl), -CON (C 1-4 alkyl) 2 , or pyrazolyl unsubstituted or substituted with C 1-4 haloalkyl; or R 1 and R 3 , together with each other, links X 1 and X 2 via a double bond, and A is benzene, pyridine, pyrimidine, or pyrimidinedione ring, wherein A is unsubstituted or substituted with one to three substituents each independently selected from the group consisting of a ring-type substituent selected from the group consisting of furanyl, imidazolyl, isoxazolyl, phenyl, pyrazolyl, pyridinonyl, pyridinyl, pyrrolyl, thiazolyl, and thiophenyl; C 1-4 alkyl; C 1-4 alkoxy; C 1-4 haloalkyl; C 1-4 haloalkoxy; halogen; di(C 1-4 alkyl)amino; nitro; -COO(C 1-4 alkyl); dihydropyranyl; morpholino; piperidinyl; and pyrrolidinyl; and wherein the ring-type substituent is unsubstituted or substituted with one or two substituents each independently selected from the group consisting of C 1-5 alkyl, C 1-4 haloalkyl, C 3-6 cycloalkyl, monovalent of C 2-5 alkylene carbonate, -COO(C 1-4 alkyl), halogen, cyano, thiazolyl, and (1,3-dioxolan-2-yl)methyl. n is 1 or 2, L is -CH 2 CH 2 -, -CH=C(R')-, or -C≡C-, wherein R' is hydrogen, C 1-4 alkyl, or halogen, X 1 is CR 1 R 2 , NR 1 , or -CO-, X 2 is CR 3 R 4 , or NR 3 , wherein R 1 to R 4 are each independently hydrogen, C 1-4 alkyl, C 1-4 hydroxyalkyl, hydroxy, amino, carboxy, -COO(C 1-4 alkyl), -CONH 2 , -CONH(C 1-4 alkyl), -CON (C 1-4 alkyl) 2 , or pyrazolyl unsubstituted or substituted with C 1-4 haloalkyl; or R 1 and R 3 , together with each other, links X 1 and X 2 via a double bond, and A is benzene, pyridine, pyrimidine, or pyrimidinedione ring, wherein A is unsubstituted or substituted with one to three substituents each independently selected from the group consisting of a ring-type substituent selected from the group consisting of furanyl, imidazolyl, isoxazolyl, phenyl, pyrazolyl, pyridinonyl, pyridinyl, pyrrolyl, thiazolyl, and thiophenyl; C 1-4 alkyl; C 1-4 alkoxy; C 1-4 haloalkyl; C 1-4 haloalkoxy; halogen; di(C 1-4 alkyl)amino; nitro; -COO(C 1-4 alkyl); dihydropyranyl; morpholino; piperidinyl; and pyrrolidinyl; and wherein the ring-type substituent is unsubstituted or substituted with one or two substituents each independently selected from the group consisting of C 1-5 alkyl, C 1-4 haloalkyl, C 3-6 cycloalkyl, monovalent of C 2-5 alkylene carbonate, -COO(C 1-4 alkyl), halogen, cyano, thiazolyl, and (1,3-dioxolan-2-yl)methyl. wherein A is unsubstituted or substituted with one to three substituents each independently selected from the group consisting of a ring-type substituent selected from the group consisting of furanyl, imidazolyl, isoxazolyl, phenyl, pyrazolyl, pyridinonyl, pyridinyl, pyrrolyl, thiazolyl, and thiophenyl; C 1-4 alkyl; C 1-4 alkoxy; C 1-4 haloalkyl; C 1-4 haloalkoxy; halogen; di(C 1-4 alkyl)amino; nitro; -COO(C 1-4 alkyl); dihydropyranyl; morpholino; piperidinyl; and pyrrolidinyl; and wherein the ring-type substituent is unsubstituted or substituted with one or two substituents each independently selected from the group consisting of C 1-5 alkyl, C 1-4 haloalkyl, C 3-6 cycloalkyl, monovalent of C 2-5 alkylene carbonate, -COO(C 1-4 alkyl), halogen, cyano, thiazolyl, and (1,3-dioxolan-2-yl)methyl. <EOS>